Novo, Wegovy and Zepbound
Digest more
The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published, examining their ability to reduce weight and waist circumference. And one clearly comes out on top.
1d
MedPage Today on MSNZepbound and Wegovy Go Head to Head for Obesity: And the Winner Is ...Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial.
GLP-1 drug Zepbound leads to greater weight and waist loss than Wegovy in 72-week trial, say researchers at European Congress on Obesity comparing new-generation weight-loss drugs
During the trial, 6.1% of participants taking Zepbound discontinued treatment due to adverse events, compared to 8.0% of participants taking Wegovy. However, the study was not powered to compare ...